open access
Analysis of the clinical and pathological characteristics of patients with the squamous-cell lung carcinoma including group survival rates and the occurrence of symptoms depending on the extent of the tumor
Affiliations- Medical University of Silesia, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
- Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
- Department of Thoracic Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
open access
Abstract
Introduction.Non-small-cell lung carcinoma (NSCLC) constitutes 80% of all lung cancer cases, of which 25–30% are squamous-cell carcinoma (SCC). We investigated the impact of comorbidities and other risk factors on the survival of patients with SCC, including the correlation between symptoms and the maximum tumor size.
Materials and methods.The study cohort included 417 patients. The Kaplan-Meier method, the Log-rank test, Gehan’s generalized Wilcoxon test, the Mann-Whitney U test, the t-test and Cox’s model of proportionality of hazards were applied.
Results.The maximum tumor size exhibited a significant correlation with the presence of symptoms such as cough, hemoptysis, and weight loss. Patients who presented with a positive family history of cancer, a prior history of cancer, respiratory diseases, or hypertension experienced a notably reduced survival time.
Conclusions.Patient’s symptoms and their medical history are important in predicting survival.
Abstract
Introduction.Non-small-cell lung carcinoma (NSCLC) constitutes 80% of all lung cancer cases, of which 25–30% are squamous-cell carcinoma (SCC). We investigated the impact of comorbidities and other risk factors on the survival of patients with SCC, including the correlation between symptoms and the maximum tumor size.
Materials and methods.The study cohort included 417 patients. The Kaplan-Meier method, the Log-rank test, Gehan’s generalized Wilcoxon test, the Mann-Whitney U test, the t-test and Cox’s model of proportionality of hazards were applied.
Results.The maximum tumor size exhibited a significant correlation with the presence of symptoms such as cough, hemoptysis, and weight loss. Patients who presented with a positive family history of cancer, a prior history of cancer, respiratory diseases, or hypertension experienced a notably reduced survival time.
Conclusions.Patient’s symptoms and their medical history are important in predicting survival.
Keywords
lung; carcinoma; squamous-cell; survival analysis
About this articleTitle
Analysis of the clinical and pathological characteristics of patients with the squamous-cell lung carcinoma including group survival rates and the occurrence of symptoms depending on the extent of the tumor
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Research paper (original)
Pages
338-346
Published online
2023-12-27
Page views
328
Article views/downloads
173
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2023;73(6):338-346.
Keywords
lung
carcinoma
squamous-cell
survival analysis
Authors
Weronika Targosz
Julia Świerczek
Błażej Ochman
Paweł Kiczmer
Paweł Ziora
Mateusz Rydel
Damian Czyżewski
Maciej Borowiecki
Bogna Drozdowska
References (16)- 39-All-Cancers-Fact-Sheet.Pdf.
- Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013; 5 Suppl 4(Suppl 4): S389–S396.
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Jackson SS, Marks MA, Katki HA, et al. Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors. Cancer. 2022; 128(19): 3531–3540.
- Green J, Cairns BJ, Casabonne D, et al. Million Women Study collaborators. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011; 12(8): 785–794.
- Drilon A, Rekhtman N, Ladanyi M, et al. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 2012; 13(10): e418–e426.
- Tsai JC, Saad OA, Magesh S, et al. Tobacco Smoke and Electronic Cigarette Vapor Alter Enhancer RNA Expression That Can Regulate the Pathogenesis of Lung Squamous Cell Carcinoma. Cancers (Basel). 2021; 13(16).
- Kim AS, Ko HJ, Kwon JH, et al. Exposure to Secondhand Smoke and Risk of Cancer in Never Smokers: A Meta-Analysis of Epidemiologic Studies. Int J Environ Res Public Health. 2018; 15(9).
- Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Health. 2019; 85(1).
- Iachina M, Jakobsen E, Møller H, et al. The effect of different comorbidities on survival of non-small cells lung cancer patients. Lung. 2015; 193(2): 291–297.
- Islam KM, Jiang X, Anggondowati T, et al. Comorbidity and Survival in Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2015; 24(7): 1079–1085.
- Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003; 103(6): 792–802.
- Agarwal M, Brahmanday G, Chmielewski GW, et al. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer. 2010; 68(3): 398–402.
- Herndon J, Fleishman S, Kornblith A, et al. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer. 1999; 85(2): 333–340, doi: 10.1002/(sici)1097-0142(19990115)85:2<333::aid-cncr10>3.0.co;2-q.
- Montazeri A, Milroy R, Hole D, et al. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer. 2001; 31(2-3): 233–240.
- Osowiecka K, Rucińska M, Każarnowicz A, et al. Przeżycia chorych na niedrobnokomórkowego raka płuca leczonych napromienianiem w latach 2003–2006 w Samodzielnym Publicznym Zakładzie Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie. Nowotwory. Journal of Oncology. 2015; 65(1): 14–22.